Rockefeller Capital Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.04M Sell
19,166
-877
-4% -$48.9K ﹤0.01% 1597
2025
Q4
$1.12M Buy
20,043
+627
+3% +$32.5K ﹤0.01% 1508
2025
Q3
$931K Sell
19,416
-979
-5% -$43.8K ﹤0.01% 1453
2025
Q2
$828K Sell
20,395
-36,945
-64% -$1.49M ﹤0.01% 1396
2025
Q1
$2.51M Buy
+57,340
New +$2.53M 0.01% 945
2023
Q1
Sell
-3,014
Closed -$123K 3916
2022
Q4
$123K Buy
+3,014
New +$125K ﹤0.01% 1923
2022
Q3
Sell
-5,199
Closed -$218K 4437
2022
Q2
$218K Buy
+5,199
New +$218K ﹤0.01% 1602

Other funds holding XPH

Rockefeller Capital Management's XPH Position: Q1 2026 in Review

Rockefeller Capital Management reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 4.4% in Q1 2026, selling an estimated $48.9K and leaving 19,166 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1597.

Rockefeller Capital Management first reported a position in XPH in Q2 2022 and has held it in 7 quarters since. The position peaked at $2.51M in Q1 2025. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.

  • Rockefeller Capital Management held 19,166 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.04M as of Q1 2026.
  • Rockefeller Capital Management sold 877 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2026, an estimated $48.9K.
  • State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1597 holding.
  • Rockefeller Capital Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2022 and has held it in 7 quarters since.
  • Rockefeller Capital Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.51M in Q1 2025.
  • 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.